Revolutionizing Peptide-Based Drug Discovery: Advances in the Post-AlphaFold Era.

Area of Science:

• Computational drug discovery
• Peptide therapeutics
• Structural biology

Background:

• Peptide-based drugs offer high specificity and potency but face challenges due to flexibility and conformational changes.
• Traditional drug discovery pipelines struggle with the unique properties of peptides.
• Advancements in Artificial Intelligence (AI) and AlphaFold (AF) present new opportunities for peptide drug development.

Purpose of the Study:

• To explore recent advancements in peptide drug discovery pipelines.
• To consider strategies for enhancing peptide stability and bioavailability.
• To evaluate the role of AI and physics-based methods in peptide drug design.

Main Methods:

• Utilized AlphaFold (AF) for accurate prediction of peptide-protein structures.
• Leveraged AI-based methods for ranking peptide binders and designing novel sequences.
• Employed physics-based methods, including molecular dynamics (MD) simulations, for insights into binding mechanisms and properties.

Main Results:

• AF enables efficient and accurate structure prediction, a critical step in computational drug discovery.
• AI shows potential in ranking binders, classifying binders/non-binders, and designing new peptide sequences.
• Physics-based methods remain crucial due to limitations in AI datasets, particularly for modified amino acids and cyclization.

Conclusions:

• A synergistic integration of AI and physics-based methods is essential for advancing peptide-based drug discovery.
• These combined approaches promise to overcome challenges related to peptide flexibility and improve therapeutic outcomes.
• The evolving landscape necessitates a hybrid strategy for successful peptide drug development.